Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Liabilities and Shareholders Equity for 12 consecutive years, with $758.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 23.06% year-over-year to $758.8 million; the TTM figure through Mar 2026 stood at $3.4 billion (down 24.59% YoY), while the FY2025 annual figure was $842.1 million, down 29.29% from the prior year.
• Liabilities and Shareholders Equity declined to $758.8 million in Q1 2026 per NTLA's latest filing, from $842.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q4 2022 and bottomed at $758.8 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 67.78% — and 2025, when it declined 29.29%.
• Intellia Therapeutics' Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then dropped by 14.42% to $1.3 billion in 2023, then declined by 8.45% to $1.2 billion in 2024, then slipped by 29.29% to $842.1 million in 2025, then decreased by 9.9% to $758.8 million in 2026.
• Business Quant data shows NTLA's Liabilities and Shareholders Equity at $758.8 million in Q1 2026, $842.1 million in Q4 2025, and $925.3 million in Q3 2025.